Shorter radiation may be just as good for rectal cancer patients
NCT ID NCT07258797
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two standard radiotherapy approaches—short-course (1 week) and long-course (several weeks)—given before surgery to people with locally advanced rectal cancer. The goal is to see which one works better at shrinking tumors and is easier for patients to tolerate. About 150 participants will be randomly assigned to one of the two treatments, and their outcomes will be tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy (short-course or long-course) plus chemotherapy (modified FOLFOX6 or mFOLFIRINOX)
What this could lead to
If successful, this study could show that a shorter radiotherapy course is just as effective as the longer one, potentially reducing treatment burden for patients with rectal cancer.
What could go wrong
This is a single-institution study with 150 participants, so results may not apply broadly. Both treatments are standard, so no major breakthrough is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE RECTUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rajiv Gandhi Cancer Institute and Research Centre
New Delhi, 110085, India
Contact Phone: •••-•••-•••• Email: •••••@•••••